Zealand Pharma initiates dosing of patients in Phase 2 with ZP4207
Friday, February 05, 2016
Zealand initiates dosing of patients in Phase 2 with its stable glucagon analogue, ZP4207, for hypoglycemia in diabetes.
Trial completion and results are expected in H2 2016.
reuters.com
